WuXi Biologics and Bioasis Technologies, Inc. have entered an initial strategic collaboration for the development and manufacture of xB3-001, Bioasis’ lead biologic candidate to treat brain cancer. 
 
Bioasis is developing xB3, a platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders, including brain cancers and neurodegenerative diseases.
 
Headquartered in Wuxi city, Jiangsu province, China, WuXi Biologics is a global platform company providing services for biologics discovery, development and manufacturing.

The delivery of most biologics across the blood brain barrier has been a challenge to treat brain diseases. Bioasis is engineering its first biologic product candidate, xB3-001, to overcome this obstacle in brain cancer. Manufacturing these sophisticated therapies requires a tailor-made approach, with expertise and agility in cell line, process and formulation development.

Bioasis will have access to WuXi Biologics’ expertise and technologies from cell line construction and development, cell culture process development, purification process development and formulation development. WuXi Biologics will focus on ensuring that Bioasis’ drug product candidates are manufactured with optimal formulation, stability and quality for the clinic.

“The initiation of manufacturing for xB3-001 is a pivotal milestone for Bioasis as we look to advance our lead program in HER2+ breast cancer brain metastases,” said Dr. Mark Day, president and chief executive officer, Bioasis. “WuXi Biologics’ expertise and experience in manufacturing biologics is instrumental to Bioasis in developing our pipeline.”

“We are excited to take on this work with Bioasis to enable them to bring innovative therapies to patients suffering from brain cancer,” said Dr. Chris Chen, chief executive officer of WuXi Biologics. “This collaboration allows us to leverage our expertise across biological drug development and anticipate Bioasis’ needs as they move from pre-clinical to clinical and beyond.”